BioGaia already has an agreement with Unilab Group for distribution of the tablets in the Philippines, and with Unilab's subsidiary in China, SUCB, for the drops.
18 April 2012 --- BioGaia has signed an agreement with Unilab Group, for the exclusive rights to sell BioGaia's probiotic drops and tablets in Taiwan. The products will be sold under the BioGaia brand and launch is planned to 2012.
Unilab Group, based in the Philippines, is a leading pharmaceutical and healthcare company in South East Asia. In Taiwan a distributor called Avipha Biotechnology Co., Ltd, will sell the products, which will be marketed under BioGaia's own brand. Both products contain BioGaia's patented and well-researched probiotic strain Lactobacillus reuteri Protectis. Today the drops are available in 51 countries worldwide and the tablets in 46.
BioGaia already has an agreement with Unilab Group for distribution of the tablets in the Philippines, and with Unilab's subsidiary in China, SUCB, for the drops.
“We are pleased with the agreement with Unilab/Avipha. As Taiwan has a population of 23 million people and the standard of living is among the top 20 countries of the world, the potential for our probiotic products should be good,” says Peter Rothschild, President, BioGaia.

Upcoming webinars

The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
Novonesis

From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot

Top Nutrition Trends 2027
Nutrition Insight










